Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies

This study has been terminated.
Information provided by (Responsible Party):
Medivation, Inc. Identifier:
First received: July 13, 2011
Last updated: December 15, 2015
Last verified: December 2015
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: May 2014
  Primary Completion Date: March 2014 (Final data collection date for primary outcome measure)